Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 8/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | SCD | O00767 | 1/20 | 0.42 |
| ▸ | NAPEPLD | Q6IQ20 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24179503 | 0.89 | HIF1A (0.52) | MAPK1GSK3BCLK1DYRK1ASCD | |
| SCHEMBL22011144 | 0.88 | MAPK1 (0.47) | MAPK1GSK3BTP53CLK1DYRK1A | |
| SCHEMBL24179276 | 0.88 | MAPK1 (0.40) | MAPK1GSK3BTP53CLK1DYRK1A | |
| SCHEMBL22011141 | 0.85 | MAPK1 (0.52) | MAPK1GSK3BTP53CLK1DYRK1A | |
| SCHEMBL21961944 | 0.77 | SNCA (0.51) | MAPK1GSK3BCLK1DYRK1ASNCA | |
| SCHEMBL21961959 | 0.77 | MAPK1 (0.49) | MAPK1GSK3BCLK1DYRK1ASMN1; SMN2 | |
| SCHEMBL21962009 | 0.76 | CLK1 (0.54) | MAPK1GSK3BCLK1DYRK1A | |
| SCHEMBL22011267 | 0.75 | MAPK1 (0.49) | MAPK1GSK3BCLK1DYRK1APOLB | |
| SCHEMBL31689710 | 0.75 | MAPK1 (0.49) | MAPK1GSK3BCLK1DYRK1APOLB | |
| SCHEMBL21961937 | 0.74 | MAPK1 (0.51) | MAPK1GSK3BTP53CLK1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220002294-A1 | ERK INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-01-06 | — | — | US | disclosed |
| CN-113423707-A | ERK inhibitors and uses thereof | 加利福尼亚技术学院 | 2021-09-21 | — | — | CN | disclosed |
| WO-2020102686-A1 | ERK INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002294-A1 | ERK INHIBITORS AND USES THEREOF | MAPKAPK2, MAPK3, MAP4K2 | MAPK1 11/4885GSK3B 358/4885TP53 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.